Xu-Ying Huang

Sauchinone inhibits angiotensin II‐induced proliferation and migration of vascular smooth muscle cells

Ying Wang, Xiaoming Li, Xu-Ying Huang, 2020, Clinical and experimental pharmacology & physiology.

A targetable MYBL2-ATAD2 axis governs cell proliferation in ovarian cancer

Jian Liu, Y. Ge, Jinwei Miao, 2022, Cancer Gene Therapy.

Inhibition of DCLK1 sensitizes resistant lung adenocarcinomas to EGFR-TKI through suppression of Wnt/β-Catenin activity and cancer stemness.

Jian Liu, Shucai Zhang, Y. Ge, 2022, Cancer letters.

Bio-informatics and in Vitro Experiments Reveal the Mechanism of Schisandrin A Against MDA-MB-231 cells

Xin Liu, Xu-Ying Huang, Li-Quan Ren, 2021, Bioengineered.

Inhibition of DCLK1 kinase reverses epithelial-mesenchymal transition and restores T-cell activity in pancreatic ductal adenocarcinoma

Jian Liu, Y. Ge, G. An, 2022, Translational oncology.

DCLK1-Short Splice Variant Promotes Esophageal Squamous Cell Carcinoma Progression via the MAPK/ERK/MMP2 Pathway

Jian Liu, Y. Ge, N. Weygant, 2021, Molecular Cancer Research.

Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling

Jian Liu, Y. Ge, Jiannan Yao, 2023, Breast Cancer Research.

DCLK1 Drives EGFR-TKI-Acquired Resistance in Lung Adenocarcinoma by Remodeling the Epithelial–Mesenchymal Transition Status

Jian Liu, Y. Ge, G. An, 2023, Biomedicines.